Download PDF
Z Gastroenterol 2014; 52(2): 204-211
DOI: 10.1055/s-0033-1355818
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Adalimumab in der Behandlung der Colitis ulcerosa – ein Konsensus der Arbeitsgruppe Chronisch Entzündliche Darmerkrankungen der Österreichischen Gesellschaft für Gastroenterologie und Hepatologie

Adalimumab for the Treatment of Ulcerative Colitis – A Consensus Report by the Working Group Inflammatory Bowel Diseases of the Austrian Society of Gastroenterology and Hepatology
G. Novacek
1   Medizinische Universität Wien, Universitätsklinik für Innere Medizin III, Klinische Abteilung für Gastroenterologie und Hepatologie, Wien, Österreich
,
C. Dejaco
1   Medizinische Universität Wien, Universitätsklinik für Innere Medizin III, Klinische Abteilung für Gastroenterologie und Hepatologie, Wien, Österreich
,
P. Knoflach
2   Klinikum Wels, 1. Interne Abteilung, Wels, Österreich
,
A. Moschen
3   Medizinische Universität Innsbruck, Universitätsklinik für Innere Medizin I, Innsbruck, Österreich
,
W. Petritsch
4   Medizinische Universität Graz, Universitätsklinik für Innere Medizin, Klinische Abteilung für Gastroenterologie und Hepatologie, Graz, Österreich
,
H. Vogelsang
1   Medizinische Universität Wien, Universitätsklinik für Innere Medizin III, Klinische Abteilung für Gastroenterologie und Hepatologie, Wien, Österreich
,
W. Reinisch
1   Medizinische Universität Wien, Universitätsklinik für Innere Medizin III, Klinische Abteilung für Gastroenterologie und Hepatologie, Wien, Österreich
› Author Affiliations
Further Information

Publication History

06 July 2013

27 September 2013

Publication Date:
31 January 2014 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

TNF-alpha-Antikörper haben den Verlauf der mittelschweren bis schweren aktiven Colitis ulcerosa wesentlich verbessert. Adalimumab ist der erste vollständig humane, monoklonale TNF-alpha-Antikörper, den Patienten selbst subkutan applizieren können. Adalimumab ist seit April 2012 zur Behandlung der mittelschweren bis schweren, aktiven Colitis ulcerosa bei Patienten zugelassen, bei denen mit einer adäquaten Therapie mit einem Glukokortikoid und einem Immunsuppressivum kein ausreichendes Ansprechen erzielt werden konnte, oder die eine entsprechende Unverträglichkeit aufweisen oder bei denen diese Therapien kontraindiziert sind. Mit Adalimumab können verglichen mit Placebo bei Patienten mit mittelschwerer bis schwerer aktiver Colitis ulcerosa häufiger eine klinische Remission und eine mukosale Heilung induziert und aufrechterhalten werden, die Zahl der Colitis ulcerosa-bedingten Krankenhausaufenthalte verringert sowie die gesundheitsbezogene Lebensqualität verbessert werden. Der Wirkungseintritt kann bereits nach 2 Wochen der Therapie erfolgen. Die Sicherheitsdaten von Adalimumab entsprechen weitgehend jenen anderer TNF-alpha-Blocker. In den bisher publizierten Studien zum Einsatz von Adalimumab bei Colitis ulcerosa wurden keine neuen Sicherheitsfragen aufgeworfen. Der vorliegende Konsensusbericht der Arbeitsgruppe Chronisch Entzündliche Darmerkrankungen der Österreichischen Gesellschaft für Gastroenterologie und Hepatologie (ÖGGH) fasst die aktuelle Datenlage zu Adalimumab in der Behandlung der Colitis ulcerosa zusammen und soll als praktischer Leitfaden für die Anwendung von Adalimumab bei Patienten mit Colitis ulcerosa dienen.

Abstract

TNF alpha antibodies have clearly improved the outcome of moderately to severely active ulcerative colitis. Adalimumab is the first fully human, monoclonal TNF alpha antibody, which is administered subcutaneously. Since April 2012 adalimumab is approved for the treatment of moderately to severely active ulcerative colitis in patients who have not responded despite a full and adequate course of therapy with a corticosteroid and an immunosuppressant or who are intolerant to or have medical contraindications for such therapies. Adalimumab can induce and maintain clinical remission and mucosal healing compared to placebo in moderately to severely active ulcerative colitis, can reduce the rate of ulcerative colitis related hospitalisations and improve health-related quality of life. The response can be observed after two weeks of treatment. The safety profile of adalimumab is comparable to those of other TNF alpha inhibitors. Studies on the treatment of ulcerative colitis with adalimumab did not reveal new safety aspects. The present consensus report by the Working Group Inflammatory Bowel Diseases of the Austrian Society of Gastroenterology and Hepatology presents the existing evidence of adalimumab for the treatment of ulcerative colitis and is aimed to assist as code of its practice.

Schlüsselwörter

Colitis ulcerosa - chronisch entzündliche Darmerkrankung - TNF-alpha-Blocker

Key words

ulcerative colitis - chronic inflammatory bowel disease - TNF alpha inhibitor
 

  • Literatur

  • 1 Dignass A, Lindsay JO, Sturm A et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012; 6: 991-1030
    CrossrefPubMedGoogle Scholar
  • 2 Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med 2011; 365: 1713-1725
    CrossrefPubMedGoogle Scholar
  • 3 Sartor RB. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology 1994; 106: 533-539
    PubMedGoogle Scholar
  • 4 Braegger CP, Nicholls S, Murch SH et al. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992; 339: 89-91
    CrossrefPubMedGoogle Scholar
  • 5 Murch SH, Braegger CP, Walker-Smith JA et al. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993; 34: 1705-1709
    CrossrefPubMedGoogle Scholar
  • 6 Murch SH, Lamkin VA, Savage MO et al. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991; 32: 913-917
    CrossrefPubMedGoogle Scholar
  • 7 Austria Codex Fachinformation: Humira® 40mg Injektionslösung in Fertigspritze. (Stand der Information: Februar 2013).
    PubMedGoogle Scholar
  • 8 Reinisch W, Sandborn WJ, Hommes DW et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60: 780-787
    CrossrefPubMedGoogle Scholar
  • 9 Sandborn WJ, van Assche G, Reinisch W et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257-265
    CrossrefPubMedGoogle Scholar
  • 10 Novacek G, Haas T, Knoflach P et al. Adalimumab in der Behandlung des adulten Morbus Crohn – Update eines Konsensus der Arbeitsgruppe Chronisch Entzündliche Darmerkrankungen der Österreichischen Gesellschaft für Gastroenterologie und Hepatologie (Adalimumab for the treatment of adult Crohn’s disease – update of a Consensus Report by the Working Group Inflammatory Bowel Disease of the Austrian Society of Gastroenterology and Hepatology). Z Gastroenterol 2013; 51: 1101-1109
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Afif W, Leighton JA, Hanauer SB et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis 2009; 15: 1302-1307
    CrossrefPubMedGoogle Scholar
  • 12 Barreiro-de AcostaM, Lorenzo A, Dominguez-Munoz JE. Adalimumab in ulcerative colitis: two cases of mucosal healing and clinical response at two years. World J Gastroenterol 2009; 15: 3814-3816
    CrossrefPubMedGoogle Scholar
  • 13 Peyrin-Biroulet L, Laclotte C, Roblin X et al. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol 2007; 13: 2328-2332
    PubMedGoogle Scholar
  • 14 Colombel JF, Sandborn W, Wolf D et al. Long-term efficacy of adalimumab for treatment of moderately to severely active ulcerative colitis. Inflamm Bowel Dis 2012; 18: S20-S21
    PubMedGoogle Scholar
  • 15 Taxonera C, Estelles J, Fernandez-Blanco I et al. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther 2011; 33: 340-348
    CrossrefPubMedGoogle Scholar
  • 16 McDermott E, Murphy S, Keegan D et al. Efficacy of Adalimumab as a long term maintenance therapy in ulcerative colitis. J Crohns Colitis 2013; 7: 150-153
    CrossrefPubMedGoogle Scholar
  • 17 Oussalah A, Laclotte C, Chevaux JB et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther 2008; 28: 966-972
    CrossrefPubMedGoogle Scholar
  • 18 Gies N, Kroeker KI, Wong K et al. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. Aliment Pharmacol Ther 2010; 32: 522-528
    CrossrefPubMedGoogle Scholar
  • 19 Sandborn WJ, Colombel JF, D'Haens G et al. One-year maintenance outcomes among patients with moderatly-to-severly active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther 2013; 37: 204-213
    CrossrefPubMedGoogle Scholar
  • 20 Reinisch W, Sandborn WJ, Panaccione R et al. 52-Week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Inflamm Bowel Dis 2013; 19: 1700-1709
    PubMedGoogle Scholar
  • 21 Wolf D, D'Haens G, Sandborn WJ et al. Rate of and response to dose escalation in patients treated with adalimumab for moderately to severely active ulcerative colitis: subanalysis of ULTRA 2. Am J Gastroenterol 2012; 107: S619
    PubMedGoogle Scholar
  • 22 D'Haens G, Sandborn WJ, Feagan BG et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132: 763-786
    CrossrefPubMedGoogle Scholar
  • 23 Peyrin-Biroulet L, Ferrante M, Magro F et al. Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis 2011; 5: 477-483
    CrossrefPubMedGoogle Scholar
  • 24 Colombel JF, Rutgeerts P, Reinisch W et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141: 1194-1201
    CrossrefPubMedGoogle Scholar
  • 25 Parente F, Molteni M, Marino B et al. Are colonoscopy and bowel ultrasound useful for assessing response to short-term therapy and predicting disease outcome of moderate-to-severe forms of ulcerative colitis? A prospective study. Am J Gastroenterol 2010; 105: 1150-1157
    CrossrefPubMedGoogle Scholar
  • 26 Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476
    CrossrefPubMedGoogle Scholar
  • 27 Ardizzone S, Cassinotti A, Duca P et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2011; 9: 483-489
    CrossrefPubMedGoogle Scholar
  • 28 Frøslie KF, Jahnsen J, Moum BA et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412-422
    CrossrefPubMedGoogle Scholar
  • 29 Ferrante M, Vermeire S, Fidder H et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis 2008; 2: 219-225
    CrossrefPubMedGoogle Scholar
  • 30 Sandborn WJ, Rutgeerts P, Feagan BG et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009; 137: 1250-1260
    CrossrefPubMedGoogle Scholar
  • 31 Rutter M, Saunders B, Wilkinson K et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126: 451-459
    CrossrefPubMedGoogle Scholar
  • 32 Bitton A, Peppercorn MA, Antonioli DA et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001; 120: 13-20
    CrossrefPubMedGoogle Scholar
  • 33 D'Haens G, Van Assche G, Wolf D et al. Mucosal healing in ulcerative colitis patients with week 8 response to adalimumab: subanalysis of ULTRA 2. Inflamm Bowel Dis 2012; 18: S21
    PubMedGoogle Scholar
  • 34 Armuzzi A, Biancone L, Daperno M et al. Adalimumab in active ulcerative colitis: A “real-life” observational study. Dig Liver Dis 2013; (epub ahead of print)
    PubMedGoogle Scholar
  • 35 Leonard P, Yang M, Chao J et al. Complications associated with colectomy in patients with ulcerative colitis. Gastroenterology 2012; 142: S-401
    CrossrefPubMedGoogle Scholar
  • 36 Loftus Jr EV, Leonard P, Yang M et al. A retrospective study of colectomy complications and their associated costs for patients with ulcerative colitis. Gastroenterology 2012; 142: S-198
    PubMedGoogle Scholar
  • 37 Sandborn WJ, Van Assche GA, Thakkar R et al. Adalimumab Improves Health-Related Quality of Life for 52 Weeks in Patients With Ulcerative Colitis. Gastroenterology 2011; 140: S-263
    PubMedGoogle Scholar
  • 38 Sandborn WJ, Colombel JF, Yang M et al. Sustained clinical remission of ulcerative colitis is associated with greater improvements in quality of life, work productivity and activity. Am J Gastroenterol 2011; 106: S 456
    PubMedGoogle Scholar
  • 39 Van Assche G, Wolf D, D'Haens G et al. Reduced steroid usage in ulcerative colitis patients with week 8 response to adalimumab: subanalysis of ULTRA 2. Am J Gastroenterol 2012; 107: S611
    PubMedGoogle Scholar
  • 40 Feagan BG, Sandborn WJ, Skup M et al. Adalimumab therapy reduces hospitalization and colectomy rates in patients with ulcerative colitis among initial responders. Am J Gastroenterol 2012; 107: S642
    PubMedGoogle Scholar
  • 41 Feagan BG, Sandborn WJ, Thakkar RB et al. Adalimumab induction dose reduces the risk of hospitalizations and colectomies in patients with ulcerative colitis during the first 8 weeks of therapy. Am J Gastroenterol 2012; 107: S647
    PubMedGoogle Scholar
  • 42 Colombel JF, Thakkar RB, Robinson AM et al. Comparative colorectal cancer risk in patients with ulcerative colitis treated with adalimumab versus conventional therapy. Am J Gastroenterol 2012; 107: S645
    PubMedGoogle Scholar
  • 43 Waterman M, Xu W, Dinani A et al. Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease. Gut 2013; 62: 387-394
    CrossrefPubMedGoogle Scholar
  • 44 Nørgard BM, Nielsen J, Qvist N et al. Pre-operative use of anti-TNF-alpha agents and the risk of post-operative complications in patients with ulcerative colitis – a nationwide cohort study. Aliment Pharmacol Ther 2012; 35: 1301-1309
    CrossrefPubMedGoogle Scholar
  • 45 Yang Z, Wu Q, Wang F et al. Meta-analysis: effect of preoperative infliximab use on early postoperative complications in patients with ulcerative colitis undergoing abdominal surgery. Aliment Pharmacol Ther 2012; 36: 922-928
    CrossrefPubMedGoogle Scholar
  • 46 Appau KA, Fazio VW, Shen B et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn’s patients. J Gastrointest Surg 2008; 12: 1738-1744
    CrossrefPubMedGoogle Scholar
  • 47 Kopylov U, Ben-Horin S, Zmora O et al. Anti-tumor necrosis factor and postoperative complications in Crohn’s disease: systematic review and meta-analysis. Inflamm Bowel Dis 2012; 18: 2404-2413
    CrossrefPubMedGoogle Scholar
  • 48 Syed A, Cross RK, Flasar MH. Anti-tumor necrosis factor therapy is associated with infections after abdominal surgery in Crohn’s disease patients. Am J Gastroenterol 2013; 108: 583-593
    CrossrefPubMedGoogle Scholar
  • 49 Narula N, Charleton D, Marshall JK. Meta-analysis: peri-operative anti-TNFalpha treatment and post-operative complications in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013; 37: 1057-1064
    CrossrefPubMedGoogle Scholar
  • 50 Jürgens M, Brand S, Filik L et al. Safety of adalimumab in Crohn's disease during pregnancy: case report and review of the literature. Inflamm Bowel Dis 2010; 16: 1634-1636
    CrossrefPubMedGoogle Scholar
  • 51 Schnitzler F, Fidder H, Ferrante M et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis 2011; 17: 1846-1854
    CrossrefPubMedGoogle Scholar
  • 52 Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol 2009; 104: 228-233
    CrossrefPubMedGoogle Scholar
  • 53 Mahadevan U, Wolf DC, Dubinsky M et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11: 286-292
    CrossrefPubMedGoogle Scholar
  • 54 Zelinkova Z, van der Ent C, Bruin KF et al. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin Gastroenterol Hepatol 2013; 11: 318-321
    CrossrefPubMedGoogle Scholar
  • 55 Traussnigg S, Eser A, Primas C et al. Adalimumab (ADA) and infliximab (IFX) therapy during pregnancy in IBD: a prospective assessment of outcome, safety and cord blood levels. J Crohns Colitis 2013; 7: S252-S253
    PubMedGoogle Scholar
  • 56 Ben-Horin S, Yavzori M, Katz L et al. Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol 2010; 8: 475-476
    CrossrefPubMedGoogle Scholar